Day: March 10, 2026

VANCOUVER, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce that it will be reporting its financial results for the year ended December 31, 2025 (“Q4 2025”) after market close on Monday, March 23, 2026. The Company will be hosting a conference call to discuss Q4 2025 results on Tuesday, March 24, 2026. Conference call details are as follows:Time: 7:00 AM PT / 10:00 AM ETConference ID: 68562Local dial-in:         (+1) 289 514 5100Toll Free N. America: (+1) 800 717 1738Webcast: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=2A9CD702-2774-4357-AB08-7BF1F20DC002    ABOUT...

NINGDE, China, March 09, 2026 (GLOBE NEWSWIRE) — Oriental Rise Holdings Limited (NASDAQ: ORIS) (“Oriental Rise” or the “Company”), an integrated tea supplier in mainland China, today announced that its operating subsidiary Fujian Mindong Hong Tea Industry Technology Co., Ltd. (“Mindong Hong”) has entered into a strategic cooperation agreement with Shandong Yiyang Zhongji New Energy Co., Ltd. (“Zhongji New Energy”), a renewable energy developer, to explore the deployment of solar photovoltaic power generation systems within the Company’s tea plantation bases. The collaboration is designed to evaluate the integration of agriculture and renewable energy infrastructure, a model often referred to as “agro-photovoltaic” development, which enables solar power generation while maintaining agricultural cultivation activities. Under the...

$12 Million of Tranche Warrants Potential Financing Within One Year From Closing SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ over-allotment option for gross proceeds of approximately $6.0 million, prior to deducting underwriting commissions and offering expenses. In connection with the offering, the Company sold 12,094,631 shares of common stock (or pre-funded warrants in lieu thereof) Series J warrants to purchase 12,094,631 shares of common stock, Series K warrants to purchase 12,094,631 shares of common stock, and Series L warrants to purchase...